Kornimate/medical-research-clean huggingface dataset:
gait pattern between a cemented and non-cemented femur stem

Conditions: Gait Analysis; Hip Fractures; Hip Arthroplasty; Randomized

Summary: acute cervical femoral neck fracture patients randomized to either cemented or non-cemented stem. the investigators used gait analysis to evaluate if patients operated with a cemented stem showed more favourable hip kinematics and kinetics when compared with a group of patients operated with a non-cemented stem.

45 patients randomized to receive either a cemented or a non-cemented stem were studied . 2 years after the operation gait analysis was performed with a 16-camera motion capture system together with 2 force-plates. hip kinematics and kinetics were analysed and 70 subjects served as controls.

Eligibility criteria:
inclusion criteria: * acute collum femoris fracture exclusion criteria: -
immune response to covid-19 vaccine in recipients of living donor liver transplantation

Conditions: Liver Transplant

Summary: a prospective cohort study to evaluate the response to covid-19 vaccine in liver transplantation patients.

fifty living donor liver transplantation recipients during maintenance immunosuppression phase will be vaccinated against covid-19 followed by assessment of immune response to the vaccine and further investigation of correlation of immune response to genetic polymorphisms of hla drb1(rs2647087) gene and il-18 (rs187238 and rs917997) gene.

Eligibility criteria:
inclusion criteria: * age\>18 * at least 3 month post transplantation exclusion criteria: * pediatric recipients * active covid infection at the time of the study * pregnancy * allergy to any ingredients included in the vaccine * lactation in first six month of delivery * active acute cellular rejection proven by liver biopsy * acute febrile state with either leucopenia or leucocytosis * high dose of corticosteroid at study timing (pulse methyl prednisolone)

Keywords: liver transplantation covid-19 coronavirus vaccine
investigation of pain and symptom burden in patients with newly diagnosed head and neck cancer

Conditions: Head and Neck Cancer

Summary: rationale: collecting information by questionnaire about the quality of life of patients with head and neck cancer may help doctors learn more about the disease. purpose: this clinical trial is testing a questionnaire for assessing pain control, head and neck symptoms, and general symptoms of illness, demographics, moods, alcohol and tobacco history, and quality of life related to cancer in patients with newly diagnosed head and neck cancer.

objectives: * to pilot test a questionnaire measuring the collection of the following data from patients with newly diagnosed head and neck cancer: head and neck cancer-related symptoms, general demographics, pain control, general symptoms, mood, smoking and drinking history, and quality of life. * to identify questions that may be unclear or difficult for patients to understand. * to determine the time required for each patient to complete the questionnaire and assess the feasibility and burden to the patient. * to determine the baseline incidence of symptoms and psychosocial issues in these patients. outline: patients complete a timed questionnaire comprising questions of head and neck symptoms, demographic information, pain control, symptom control, mood, smoking and drinking history, and anxiety and depression under the supervision of the investigator.

Eligibility criteria:
inclusion criteria: * diagnosis of head or neck carcinoma * newly diagnosed disease * able to speak english * able to give informed consent exclusion criteria: not specified prior concurrent therapy: * not specified

Keywords: head and neck cancer
neoantigen-primed dc vaccines therapy for refractory lung cancer

Conditions: Carcinoma, Non-Small Cell Lung; Carcinoma, Small Cell Lung

Summary: various of immunotherapies are now widely applied in the treatment of lung cancer. neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. neoantigens are highly suitable for the development of cancer vaccines. the study aims to evaluate the safety and efficacy of neoantigen-loaded dendritic cell (dc) vaccines for refractory lung cancer.

cancer genome research has exploded benefits from the application of modern high-throughput genome sequencing in the past few years. since usually there are no common antigens expressed on the surfaces of different kinds of tumors, neoantigens which expressed specifically in the individual tumor are chosen to establish tumor-specific vaccines. 30 patients with refractory lung cancer would be enrolled and undergo tumor resection if all requirements are met. the whole-exome sequencing and the bioinformatic analysis of the resected specimens would be performed to identify the neoantigens. then, candidate neoantigens would be synthesized to pulse the matured dc cells. neoantigen-primed dc vaccines are provided to the corresponding patients. each patient would be vaccinated 6 times in total, one shot per week. patients enrolled would undergo the schemed follow-up, one time per three months. the side effects, overall survival, and progress-free survival would be recorded. at the end of the research, the safety and efficacy of neoantigen dc vaccines for refractory lung cancer would be evaluated.

Eligibility criteria:
inclusion criteria: * age ≥18 years ≤ 70 years at the time of informed consent * signed informed consent to be provided * pathologically confirmed lung cancer * failed in previous standard chemotherapy and targeted therapy * life expectancy not less than 90 days * karnofsky performance status 0-1 * adequate organ functions exclusion criteria: * actively infectious condition including hepatitis * women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant. * any form of primary immunodeficiency (such as severe combined immunodeficiency disease). * concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system. patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities). * active systemic infections, coagulation disorders or any other active major medical illnesses. * patients who are receiving any other investigational agents.

Keywords: neoantigen dentritic cell vaccine immunotherapy refractory lung cancer
molecular profiling in small cell lung cancer

Conditions: Lung Neoplasms; Small Cell Lung Cancer

Summary: this protocol is to obtain tumor tissues and blood samples from patients with a confirmed histological diagnosis of small cell lung cancer(sclc) for molecular profiling.

small cell lung cancer (sclc) is most invasive subtypes of lung cancer. after diagnosis, the sclc patients without treatment often die in 2-4 months. sclc is a highly heterogeneous malignant tumor, the previous treatment principle of the tumor is based on the traditional histopathology, which not provide accurate guidance for precise treatment. in recent years, breakthrough has been made in molecular classification of breast cancer, non-small cell lung cancer, gastrointestinal cancer and of the other tumor, but sclc molecular classification has not yet reported. in this prospective study, sclc tissues and blood samples from extensive sclc patients will be obtained and evaluated of molecular profiling. eligible population includes: patients who have not undergone any treatment and diagnosed of extensive sclc by immunohistochemistry(ihc). the purpose is to evaluate molecular profiling of sclc patients who are sensitive or resistant to chemotherapy (cisplatin+etoposide). to compare molecular alterations of sclc patients with different prognosis (overall survival, progress free survival).

Eligibility criteria:
inclusion criteria: * age: between 18 and 75 years old. * sexes eligible for study: all * diagnosed of sclc by ihc, and divided into extensive stage. * the ecog (eastern cooperative oncology group, ecog) ps(performance status，ps) scale score is 0 or 1. * at least one measurable lesions by ct scan. * expect to survive for at least three months. * peripheral blood routine and liver and kidney function meet the following criterion (blood draw 7 days before the treatment begins) : * the white blood cell (wbc) is greater than the 3.0×10\^9/l or neutrophils (anc) more than 1.5 x10\^9/l; * hemoglobin (hgb) is greater than 80 g/l. * platelet (plt) is greater than 100×10\^9/l. * (ast/alt): aspartate aminotransferase/alanine aminotransferase\<3.0 times of normal range. * total bilirubin (tbil) \< 1.5 times of normal range. * creatinine (creat) \< 1.5 times of normal range. * female or male patients must adopt effective birth control measures. * informed consent forms provided. patients must meet each of the above criteria. exclusion criteria: * other pathological types of tumors ,rather than small cell lung cancer. * incorporating other tumors in the early diagnosis; * patients who have received chemotherapy, radiotherapy or any other anti-cancer treatment. * patients that known to be allergic to the drug components involved in the study; * patients with severe allergies or allergies; * pregnant or breastfeeding women; * patients with acute infection which is difficult to control; * drug abuse, substance abuse, long-term alcohol and aids(acquired immune deficiency syndrome) patients. candidates who meet each of the exclusion criteria will not included in the research.
everolimus- versus biolimus-eluting stents in all-comers

Conditions: Coronary Artery Disease

Summary: this study sought to investigate safety and efficacy of biolimus-eluting stents (bes) with biodegradable polymer as compared with everolimus-eluting stents (ees) with durable polymer through 3 years of follow-up.

a group of 814 consecutive patients undergoing percutaneous coronary intervention (pci) was enrolled between 2007 and 2010, of which 527 were treated with ees and 287 with bes implantation. clinical outcome was compared in 200 pairs using propensity score matching. the primary endpoint was a composite of death, myocardial infarction (mi) and target vessel revascularisation (tvr) at two-year follow-up.

Eligibility criteria:
inclusion criteria: * all patients with at least one bes or ees for de novo stenosis exclusion criteria: * patients with at least one non-study stent * patients with both study stent * patients with life expectancy \< 3 years

Keywords: drug-eluting coronary stent percutaneous coronary intervention
mulligan's bent leg raise technique in healthy females

Conditions: Hamstring Contractures

Summary: to determine the effects of mulligan's bent leg raise technique on hamstring flexibility and lumber spine mobility in healthy females

flexibility is a pivotal constituent of the physical fitness and held as an integral aspect that capacitate the person to move smoothly and safely. although the flexibility of all the muscles of the body is essential for normal human function, the flexibility of hamstring muscle is much emphasized. investigations suggest adequate flexibility of the hamstring muscles is compulsory for a healthy lower back. lack of hamstring muscles extensibility conditions a decrease of pelvic mobility. this invariably leads to biomechanical changes in the pressure distribution of the spine and consequent spinal disorders. this study will be a randomized control trial and will be conducted in health sciences collage in bahawalpur. the study will be completed within the time duration of six months. convenient sampling technique will be used to collect the data. the sample size of 48 patients will be taken in this study to find the effects of mulligan's bent leg raise technique on hamstring flexibility and lumber spine mobility in healthy females. patient will be divided into two groups. static stretching will be given to both group as a baseline treatment. (group a will be treated with mulligan's bent leg raise techniques and static stretching group b will be treated with static stretching only. participants will be assessed for hamstring tightness with active knee extension test (aket) and readings will be noted and lumbar mobility will be assess using modified schober test (mmst). assessments will be done at baseline and post intervention on 5th and 10th day. intervention will be given 5 days per week for two weeks. data will be analyzed on spss 25.

Eligibility criteria:
inclusion criteria: * only healthy females will be included. * age 18-24 years. * bmi normal * hamstring muscle tightness -90-90 hip active knee extension test positive (aket). exclusion criteria: * any traumatic and infectious condition involving lower limb. * pathologies and deformities related to knee and hip joint. * any neurological symptoms affecting the lower limbs. * subjects performing regular exercises or stretching.
study to compare the efficacy of mycophenolate mofetil in systemic sclerosis related early interstitial lung disease

Conditions: Systemic Sclerosis; Scleroderma; Interstitial Lung Disease

Summary: systemic sclerosis is a multisystem disease and can involve the lungs in the form of ild. lung involvement is the most common cause of death in these patients. the present study is performed to study the efficacy of oral mycophenolate mofetil in treating early and mild ild in patients of ssc. the efficacy and side effects of mycophenolate mofetil will be compared with that of oral placebo.

lung involvement is the leading cause of death among patients with systemic sclerosis (ssc). treatment with immunosuppression drugs helps in retarding the progression of interstitial lung disease (ild) and improves the morbidity and mortality among these patients. presently, cyclophosphamide has been shown to be useful in stabilizing the lung functions among patients of systemic sclerosis with ild. but use of cyclophosphamide is also associated with many adverse effects including infections, cytopenias, gonadal dysfunction and malignancies. use of oral mycophenolate mofetil (mmf) in ssc-ild in recent studies has been shown to be effective in retarding progression of ild among these patients with a better side effect profile compared to cyclophosphamide. contemporary expert opinion dictates that the treatment for ssc-ild needs to be individualized. generally, intense immunosuppression is required in patients with fvc \ 70% of the predicted, the need for high dose immunosuppression is not clear and varies from center-to-center. the present study is designed to determine the efficacy of oral mmf in patients with ssc related early ild. the subjects in this study will be given either oral mmf or placebo and will be monitored for their response and adverse events. informed consent will be taken from the subjects before including in the study.

Eligibility criteria:
inclusion criteria: 1. patients of systemic sclerosis with presence of interstitial lung disease on high resolution computer tomography (hrct) chest 2. fvc ≥ 70% of predicted on pulmonary function tests 3. age ≥18 years 4. consenting for participating in study exclusion criteria: 1. received immunosuppression (except low dose steroids, prednisolone equivalent ≤10 mg/day) for ild in the last 3 years 2. persistent leucopenia or thrombocytopenia 3. pregnant or breastfeeding females 4. severe pulmonary arterial hypertension (mean pulmonary arterial pressure \>55mmhg) requiring drug therapy 5. uncontrolled congestive heart failure 6. any other abnormalities noted on chest x-ray or hrct other than ild 7. active infection 8. inflammatory myositis 9. overlap syndrome 10. mixed connective tissue disease 11. other serious co-morbidities which could compromise patient's ability to complete the study
a study of chidamide with aza in mrd positive aml after transplant

Conditions: AML, Adult; Minimal Residual Disease

Summary: acute myeloid leukemia (aml) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.allogeneic hematopoietic stem cell transplantation (allo-hsct) is still the primary treatment option for patients with aml and the most effective method for radical treatment of aml.despite considerable progress in allo-hsct over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with aml.

investigators proposed chidamide combined with azacitidine as the prospective treatment for mrd-positive aml patients before and after transplantation, hoping to reduce the recurrence rate of transplantation and improve the transplantation effect. the efficacy and safety of the method will be verified by this clinical study.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with aml (diagnostic criteria refer to who2016 criteria, except m3) can detect small residual lesions (mrd) positive after allogeneic hematopoietic stem cell transplantation (allo-hsct); 2. ≥18 years old; 3. ecog≤3; 4. lifespan≥3 months; 5. take contraceptive measures; 6. sign informed consent. exclusion criteria: 1. allergic to the study drug; 2. a gastrointestinal condition that prevents oral medication; 3. active infection; 4. dysfunction of vital organs; 5. other malignancies; 6. hiv infection; 7. hbv or hcv; 8. the qt interval is prolonged; 9. pregnant or lactating women; 10. is participating in other clinical studies; 11. the researchers did not consider it appropriate to participate in this study.
effect of nicotine on chronic pelvic pain

Conditions: Pelvic Pain

Summary: the purpose of this study is to test whether transdermal nicotine reduces pain among women with chronic pelvic pain.

potential subjects are female non-smokers presenting to their physicians for treatment of chronic pelvic pain. when consented, the subjects fill out a questionnaire on demographic information and pain experience. the trial is conducted at home over three days. each subject uses three different levels of nicotine (0mg, 5mg, and 10mg) administered in a random order; the study is double-blinded and patients act as their own controls. subjects apply the placebo or nicotine patches in the morning and remove them in the evening when they fill out a pain diary for the day. during the study, patients will continue their typical course of pain medication and report pain medication use in the pain diary.

Eligibility criteria:
inclusion criteria: * chronic pelvic pain * aged 18-60 years * female exclusion criteria: * uncontrolled hypertension * cardiovascular disease * current analgesic abuse * pregnancy * current usage of nicotine patch or gum * allergy to adhesive tape

Keywords: chronic pain pelvic pain nicotine patch
the efficacy of robot assisted group cognitive training in elderly adults without cognitive impairment

Conditions: Age-Related Cognitive Decline

Summary: previous studies about cognitive intervention targeting older adults revealed that cognitive training had effects on the improvement of cognitive function.however, researches are rare that investigated direct changes of brain structures after cognitive training. the advanced scientific technique allowed us to develop service robots designed to assist human work, which can be important with an increase in the aging population and high costs of elderly care. in this regard, the investigators considered robots for elderly's cognitive training and developed 17 cognitive programs in collaboration with center for intelligent robotics at korea institute of science and technology. the purposes of this study were to demonstrate the effects of the investigators newly developed robot assisted group cognitive training programs on the brain in older adults and to identify whether they can help to improve cognitive function or mood in the elderly compared to the conventional cognitive training or control group that were not involved in any cognitive training.

primary outcome the primary outcome of this study was the change in cortical thickness between the baseline and the post-intervention assessment. secondary outcomes change in the brain functional network from the baseline to the postintervention assessment was also assessed as a secondary outcome ascertained by the analysis of resting state fmri, which has been used to show correlated spontaneous activity within cortical and subcortical regions that are functionally related. further secondary outcomes were changes between the baseline and the post-intervention assessment on cognitive function measured by validated neuropsychological tests such as snsb and cantab on participants' depressive and anxiety symptoms scored by geriatric depression scale and geriatric anxiety inventory respectively, on self reported memory problems measured by korean dementia screenng questionnaire, multifactorial memory questionnaire and prospective and retrospective memory questionnaire, on functions of daily living acitivity measured by bayer adl, on quality of life measuared by whoqol-bref.

Eligibility criteria:
inclusion criteria: * community-dwelling volunteers aged 60 years or older * without dementia * mmse=26 or above exclusion criteria: * if they had known dementia or significant cognitive impairment accompanied by dysfunction of daily living activities; * had 6 years of education or under; * were illiterate * were unavailable during the testing and intervention periods of the study; * had severe losses in vision or hearing; had major neurological or psychiatric illness history including any history of stroke, transient ischemic attack or traumatic brain injury; * had a medication history which might affect on cognitive function such as acetylcholinesterase inhibitor or memantine * had medical problems such as thyroid, liver and renal disease; * had a significan structural abnormalities on their baseline brain mri.

Keywords: cognitive therapy
cardiac involvement in wilson's disease

Conditions: Wilson's Disease

Summary: heart damage by copper accumulation has been reported in wilson's disease. however, the disease epidemiology is still poorly understood. a number of studies on pediatric populations have not shown any significant cardiac involvement apart from early dysautonomia. this could suggest that the clinical manifestations related to the copper accumulation in the heart appears with the duration of the disease. case-control studies on adult populations have highlighted various electrocardiographic (ecg) abnormalities more frequent in patients with wilson's disease than in healthy volunteers, but all these studies involved small number of patients (maximum 60). the hypothesis is that there is cardiac involvement in wilson's disease, requiring screening, follow-up and appropriate support.


Eligibility criteria:
inclusion criteria: * adult patient with wilson's disease confirmed by a leipzig score ≥ 4 * express consent to participate in the study by the patient or legal guardian in the case of patients under guardianship or by the patient assisted by his curator in the case of patients under guardianship * member of or beneficiary of a social security scheme exclusion criteria: * absolute or relative contraindication to mri or contrast media * pregnant, parturient or breast-feeding women: a urine pregnancy test will be carried out in women of childbearing age * patient with hepatic decompensation (child-pugh score stage c) * patient in neuro-psychiatric decompensation